VRTX505.75-2.07%
VRTX · US
1y range: 423.24 → 529.65 · as of 2026-08-14
AI digest — today
Vertex profiteert van Sionna's klinische mislukking in cystische fibrose en bereikt nieuwe highs. Q2-resultaten tonen sterke momentum: omzet $3,33B, nettowinst $1,10B, met full-year guidance verhoogd naar $13,10–$13,20B. CASGEVY en JOURNAVX versnellen in uptake.
Generated 2026-08-12 06:01
Weekly thesis
Groeimotor met sterke Q2-beat en verhoogde guidance, maar integratie-risico's van Crinetics-deal en EPS-volatiliteit vereisen voorzichtigheid op 1-3M horizon.
Bull case
- Q2 guidance-raise naar $13,1-$13,2B full-year (+12% YoY omzet) signaleert sterke onderliggende vraag; CASGEVY en JOURNAVX tonen sequentiële groei - Crinetics-overname voegt Palsonify (direct commercieel product) toe en creëert vijfde business pillar in endocrinologie — structurele groeikatalyst voor 2026-2027 - Analyst-momentum: drie PT-verhogingen deze week ($560→$565, $615→$617), consensus zeer bullish (11 Strong Buy, 19 Buy) — upside naar $570 PT realistisch op 3-6M - ABCL-635 Phase I data verwacht 'zeer binnenkort' (menopause-indicatie) + T-cell engager deals >$110M — pijplijn-opties voor volgende groeifase - Adjusted EPS $4,73 in lijn met consensus ondanks GAAP-miss — toont operationele discipline en non-GAAP-kwaliteit
Bear case
- EPS-volatiliteit: 4 van 8 vorige quarters miss (Q2 -2%, Q4 -2,8%, Q1 -7,2%) — geen consistent outperformance, verwachtingsrisico op consensus - Netto-verlies verbreed (key facts) ondanks omzet-groei — integratie-kosten van Crinetics hoger dan verwacht, of organische marge-druk - 102% premie op Crinetics-overname + CEO-targeting van $60-70M cost-cutting suggereert post-deal-realiteit: synergieën niet vanzelfsprekend, shareholder-value-risico - Consensus zeer bullish (11 Strong Buy, 19 Buy) — verwachtingsrisico ingebakken; kleine teleurstelling (bv. ABCL-635 Phase I data zwak) kan korting triggeren - Revenue decline flagged in key facts (2026-08-06) — onduidelijk of dit Q2-specifiek is of trend; clarificatie nodig
Recent material news
- Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance2026-08-14T20:08
- Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)2026-08-14T09:40
- One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses2026-08-12T03:41
- 5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call2026-08-12T01:41
- Vertex (VRTX) Q2 2026 Earnings Call Transcript2026-08-11T01:29
- Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?2026-08-10T15:14
- AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ...2026-08-06T05:01
- AbCellera Biologics Q2 Earnings Call Highlights2026-08-05T22:03
Want this depth on every stock you watch?
ThickerPeek writes a daily AI digest on 165+ stocks, weekly theses, earnings briefings, and alerts — for €19/mo. Free tier available.
Not investment advice. ThickerPeek is a research tool. AI-written content is informational, not a buy/sell recommendation. Investment decisions are your own responsibility.